ReviewDiagnostics (Basel, Switzerland)2026
Averting Potential Misinterpretations and Diagnostic Misapplications of Misleading Laboratory Results.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis is a dynamic process, encompassing clinical presentation of pathophysiology, workup investigations and appropriate interpretations/integration of all data. Diagnostic accuracy is expected when based on multiple tests/investigations. However, when diagnosis is based on a single abnormal laboratory test, considered to be fundamental and deterministic, an early test's error could cascade and propagate, triggering unnecessary investigations, longer hospitalisation and possible diagnostic misapplications. Up to 70% of diagnoses involve laboratory tests. Immunologically based analyses (immunoassays) have two fundamental features: (a) inherently higher analytical error rate than other common routine tests such as U&E, LFT, bone profile, FBC, et cetera, and (b) universality, affecting measurements regardless of the analyte's nature or the immunoassay's provider. Averting potentially erroneous results necessitates a paradigm shift which can be made by (a) intuitive use of a statistical paradigm (Bayesian reasoning), which will be explained by a simple example and without equations, and (b) appropriate and more use of follow-up confirmatory tests when the test has consequences and potential diagnostic misapplications by using available tests in all hospital laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.